Epidemiological study of high‑risk human papillomavirus infection in subjects with abnormal cytological findings in cervical cancer screening

  • Authors:
    • Weizhi You
    • Shaocong Li
    • Ran Du
    • Jizeng Zheng
    • Aifang Shen
  • View Affiliations

  • Published online on: October 23, 2017     https://doi.org/10.3892/etm.2017.5357
  • Pages:412-418
Metrics: HTML 0 views | PDF 0 views
0

Abstract

The present study aimed to determine the genotype and age distribution of high‑risk human papillomavirus (HR‑HPV) and evaluate HPV‑DNA in subjects with abnormal cervical cytology results by using crowd‑based cervical cancer screening cytology data. The Thinprep liquid‑based cytologic test (TCT) was performed from January 2013 to January 2014 in the permanent residents of Liaocheng (China) aged 21‑65 years who were married or had sexual intercourse. The number of screened women totaled 20,017, among whom 937 had abnormal results, 785 of which were recalled. For subjects in the age range of 21‑65 years, an HR‑HPV typing test using the fluorescence hybridization method. Among the 785 cases with abnormal TCT findings, repeated testing identified atypical squamous cells of unknown significance/atypical glandular cells in 478, low‑grade squamous intraepithelial lesions in 175, high squamous intraepithelial lesions in 127 and squamous cell carcinoma/adenocarcinoma in 5 cases. Among these types, infection rates of HR‑HPV were 50.2, 77.1, 89.0 and 100%, respectively. Of the 785 cases with abnormal TCT results, 493 (62.8%) were HR‑HPV‑positive. A total of 16 types of HR‑HPV were detected: HPV‑16, ‑18, ‑31, ‑33, ‑35, ‑39, ‑45, ‑51‑53, ‑56, ‑58, ‑59, ‑66, 68 and 73. Subjects infected with ≥2 types were defined as having a multi‑type infection. The infection rate was high in the age groups of 26‑30 and 51‑55 years, accounting for 87.7% (71/81) and 79.7% (51/64), respectively, while it was lower in the >55 years group at 28.6% (14/54). The top five types of HR‑HPV (stated in a decreasing order regarding positivity rate) were HPV16 (21.5%, 169/785), HPV52 (12.2%, 96/785), HPV58 (9.8%, 77/785), HPV33 (9.7%, 76/785) and HPV18 (7.5%, 59/785). Single‑type infection was encountered in 45.0% (353/785) and multi‑type infection in 17.8% (140/785), among which 98 cases had a two‑type infection, 37 had a three‑type infection, 2 had a four‑type infection, 2 had a five‑type infection and 1 case had a six‑type infection. In the present study, differences in multi‑type HR‑HPV infection between groups with different TCT results were statistically significant. In conclusion, compared with CTC screening on its own, complementary HR‑HPV testing is an effective method for screening for cervical cancer. The infection rate of HPV16, ‑52, ‑58, ‑33 and ‑18 was high among patients with cervical cytological abnormalities. Multi‑type infection adds to the risk of malignancies. In Liaocheng, high‑risk groups were aged 26‑30 and 51‑55. Attention should be paid during the screening and follow‑up visits of these groups.

Related Articles

Journal Cover

January 2018
Volume 15 Issue 1

Print ISSN: 1792-0981
Online ISSN:1792-1015

2016 Impact Factor: 1.261
Ranked #50/128 Medicine Research and Experimental
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
You, W., Li, S., Du, R., Zheng, J., & Shen, A. (2018). Epidemiological study of high‑risk human papillomavirus infection in subjects with abnormal cytological findings in cervical cancer screening. Experimental and Therapeutic Medicine, 15, 412-418. https://doi.org/10.3892/etm.2017.5357
MLA
You, W., Li, S., Du, R., Zheng, J., Shen, A."Epidemiological study of high‑risk human papillomavirus infection in subjects with abnormal cytological findings in cervical cancer screening". Experimental and Therapeutic Medicine 15.1 (2018): 412-418.
Chicago
You, W., Li, S., Du, R., Zheng, J., Shen, A."Epidemiological study of high‑risk human papillomavirus infection in subjects with abnormal cytological findings in cervical cancer screening". Experimental and Therapeutic Medicine 15, no. 1 (2018): 412-418. https://doi.org/10.3892/etm.2017.5357